FGFR1solid tumor Test Cost AED:1800.0 – DNA Labs UAE
Are you concerned about the possibility of having a solid tumor? DNA Labs UAE offers the FGFR1solid tumor Test at an affordable cost of AED 1800.0. This test is designed to detect alterations in the FGFR1 gene, which can lead to the overexpression or activation of the FGFR1 protein, promoting tumor growth and progression.
Test Details
The FGFR1solid tumor Test analyzes paraffin embedded tissue blocks to determine the presence of FGFR1 alterations. These alterations can occur through gene amplification, gene fusion, or point mutations. The test is performed using the FISH method, which is a genetic testing technique that allows for the visualization of specific DNA sequences.
Test Components
- Paraffin embedded tissue blocks
Sample Condition
The FGFR1solid tumor Test requires tumor tissue samples for analysis. It is important to ensure that the samples are in good condition to obtain accurate results.
Report Delivery
After the samples have been analyzed, the test results will be delivered within 7-8 days. Our team at DNA Labs UAE understands the importance of timely results for effective treatment planning.
Test Type
The FGFR1solid tumor Test falls under the category of genetics testing. It aims to identify genetic alterations that may contribute to the development and progression of solid tumors.
Doctor and Test Department
The FGFR1solid tumor Test is conducted under the supervision of oncologists, who specialize in the diagnosis and treatment of cancer. Our dedicated test department ensures accurate and reliable results.
Pre Test Information
Please note that a doctor’s prescription is required for the FGFR1solid tumor Test. However, it is not applicable for surgery and pregnancy cases or individuals planning to travel abroad. This precaution is in place to ensure the safety and appropriateness of the test.
Understanding FGFR1 and Solid Tumors
The FGFR1 gene encodes for the fibroblast growth factor receptor 1 protein, which is involved in cell growth, proliferation, and differentiation. In solid tumors, alterations in the FGFR1 gene can lead to the overexpression or activation of the FGFR1 protein. This, in turn, can result in aberrant signaling pathways that promote tumor growth and progression.
FGFR1 alterations have been observed in various types of solid tumors, including lung cancer, breast cancer, gastric cancer, and bladder cancer. These alterations can occur through gene amplification, gene fusion, or point mutations.
Potential Treatment Options
Targeted therapies that specifically inhibit the FGFR1 protein have been developed and are currently being evaluated in clinical trials for the treatment of FGFR1-altered solid tumors. These therapies aim to block the abnormal signaling pathways driven by FGFR1, thereby inhibiting tumor growth.
At DNA Labs UAE, we understand the importance of early detection and personalized treatment options for solid tumors. Our FGFR1solid tumor Test provides valuable insights into the genetic alterations that may be driving tumor growth, helping oncologists make informed treatment decisions.
Don’t wait for symptoms to worsen. Take control of your health and book your FGFR1solid tumor Test at DNA Labs UAE today!
| Test Name | FGFR1solid tumor Test |
|---|---|
| Components | Paraffin embedded tissue blocks |
| Price | 1800.0 AED |
| Sample Condition | Tumor tissue |
| Report Delivery | 7-8 days |
| Method | FISH |
| Test type | Genetics |
| Doctor | Oncology |
| Test Department: | |
| Pre Test Information | FGFR1(solid tumor) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
FGFR1 is a gene that encodes for the fibroblast growth factor receptor 1 protein. This protein is a receptor tyrosine kinase that plays a role in cell growth, proliferation, and differentiation. In solid tumors, alterations in the FGFR1 gene can lead to overexpression or activation of the FGFR1 protein. This can result in aberrant signaling pathways that promote tumor growth and progression. FGFR1 alterations have been observed in various types of solid tumors, including lung cancer, breast cancer, gastric cancer, and bladder cancer. These alterations can occur through gene amplification, gene fusion, or point mutations. Targeted therapies that specifically inhibit the FGFR1 protein have been developed and are being evaluated in clinical trials for the treatment of FGFR1-altered solid tumors. These therapies aim to block the abnormal signaling pathways driven by FGFR1, thereby inhibiting tumor growth. |
